About Century Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.centurytx.com/
Frequently Asked Questions
What is the 52-week range for IPSC?
The 52-week high is $3.04 and the 52-week low is $0.435.
What is the P/E ratio for IPSC?
The P/E ratio data is currently unavailable.
What is the dividend yield for IPSC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -52.76%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -18.92%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.55.
Analyst Recommendation Trends
Wall Street analyst consensus for IPSC over the last few months:
Latest IPSC News
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027 PHILADELPHIA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived c
Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetesCNTY-813 IND
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
Century Therapeutics' CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression. Find out why IPSC stock is a buy.
Century Therapeutics Appoints Joseph Truitt to Board of Directors
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | Russotti Gregory | -2,587 | $1.93 | $4,993 |
| 2026-09-14 | Carr Douglas | -1,658 | $1.93 | $3,200 |
| 2026-09-11 | Pfeiffenberger Brent | -13,850 | $1.94 | $26,869 |
| 2026-09-09 | Truitt Joseph | +148,000 | - | - |
| 2026-09-08 | Russotti Gregory | -534 | $2.05 | $1,095 |
| 2026-09-08 | Carr Douglas | -254 | $2.05 | $521 |
| 2026-09-04 | Pfeiffenberger Brent | -463 | $2.11 | $977 |
| 2026-08-14 | Pfeiffenberger Brent | -31,172 | $1.92 | $59,850 |
| 2026-08-03 | Carr Douglas | -275 | $1.977 | $544 |
| 2026-06-12 | Russotti Gregory | -2,584 | $2.232 | $5,767 |
| 2026-06-12 | Carr Douglas | -1,654 | $2.232 | $3,692 |
| 2026-06-11 | Cowan Chad | -358 | $2.24 | $802 |
| 2026-06-11 | Pfeiffenberger Brent | -13,849 | $2.24 | $31,022 |
| 2026-06-11 | Murphy Martin Patrick | +74,000 | - | - |
| 2026-06-11 | Lee Han Myung | +74,000 | - | - |
| 2026-06-11 | Riva Alessandro | +74,000 | - | - |
| 2026-06-11 | Blackwell Kimberly | +74,000 | - | - |
| 2026-06-11 | Quimi Daphne | +74,000 | - | - |
| 2026-06-08 | Russotti Gregory | -524 | $2.111 | $1,106 |
| 2026-06-08 | Carr Douglas | -249 | $2.111 | $526 |
| 2026-06-05 | Pfeiffenberger Brent | -463 | $2.13 | $986 |
| 2026-05-15 | Pfeiffenberger Brent | -31,172 | $2.34 | $72,942 |
| 2026-05-04 | Carr Douglas | -264 | $2.341 | $618 |
| 2026-04-01 | Cowan Chad | -1,365 | $2.19 | $2,989 |
| 2026-03-12 | Russotti Gregory | -10,076 | $2.549 | $25,684 |
| 2026-03-12 | Carr Douglas | -7,043 | $2.549 | $17,953 |
| 2026-03-11 | Cowan Chad | -1,431 | $2.73 | $3,907 |
| 2026-03-11 | Pfeiffenberger Brent | -55,397 | $2.73 | $151,234 |
| 2026-03-09 | Russotti Gregory | -479 | $2.536 | $1,215 |
| 2026-03-09 | Carr Douglas | -247 | $2.536 | $626 |
| 2026-03-06 | Pfeiffenberger Brent | -463 | $2.56 | $1,185 |
| 2026-02-13 | Pfeiffenberger Brent | -31,172 | $1.75 | $54,551 |
| 2026-02-03 | Carr Douglas | -323 | $1.822 | $589 |
| 2026-02-02 | Cowan Chad | +265,000 | - | - |
| 2026-02-02 | Cowan Chad | +135,000 | - | - |
| 2026-02-02 | Pfeiffenberger Brent | +945,000 | - | - |
| 2026-02-02 | Pfeiffenberger Brent | +475,000 | - | - |
| 2026-02-02 | Russotti Gregory | +265,000 | - | - |
| 2026-02-02 | Russotti Gregory | +135,000 | - | - |
| 2026-02-02 | Carr Douglas | +225,000 | - | - |
| 2026-02-02 | Carr Douglas | +110,000 | - | - |
| 2026-01-02 | Cowan Chad | -1,611 | $0.995 | $1,603 |
| 2025-12-22 | Cowan Chad | +58,060 | $0.8483 | $49,252 |
| 2025-12-12 | Pfeiffenberger Brent | +52,000 | $0.5837 | $30,352 |
| 2025-12-10 | Pfeiffenberger Brent | -463 | $0.526 | $244 |
| 2025-12-09 | Murphy Martin Patrick | +88,000 | - | - |
| 2025-12-09 | Lee Han Myung | +88,000 | - | - |
| 2025-12-08 | Russotti Gregory | -526 | $0.532 | $280 |
| 2025-12-08 | Carr Douglas | -257 | $0.532 | $137 |
| 2025-11-20 | Cowan Chad | -5,462 | $0.501 | $2,736 |
| 2025-11-19 | Pfeiffenberger Brent | +35,000 | $0.4951 | $17,329 |
| 2025-11-17 | Pfeiffenberger Brent | -32,456 | $0.454 | $14,735 |
| 2025-11-03 | Carr Douglas | -292 | $0.586 | $171 |